Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma. (20th July 2009)

• Record Type: Journal Article
• Authors: Meyer, Stefanie; Vogt, Thomas; Landthaler, Michael; Berand, Anna; Reichle, Albrecht; Bataille, Frauke; Marx, Andreas H.; Menz, Anne; Hartmann, Arndt; Kunz-Schughart, Leoni A.; Wild, Peter J.
• Other Names: Panigrahy Dipak Academic Editor.
• Is Part Of: PPAR research. Volume 2010(2010)
• Publication Date: 2009-07-20
• Subjects: Peroxisomes -- Periodicals; Peroxisomal disorders -- Periodicals; 571.65505
• DOI: 10.1155/2010/848645
• Languages: English
• ISSNs: 1687-4757

Abstract

Abstract : Using tissue microarrays (TMAs) we studied COX2/PPARG immunoreactivity in a broad spectrum of tumors focussing on clinicopathological correlations and the outcome of patients with malignant melanoma (MM). TMA-1 contained normal and tumor tissues (n = 3448 ) from 47 organs including skin neoplasms (n = 323 ); TMA-2 88 primary MM, 101 metastases, and 161 benign nevi. Based on a biomodulatory approach combining COX/PPAR-targeting with metronomic low-dose chemotherapy metastases of 36 patients participating in a randomized trial with metastatic (stage IV) melanoma were investigated using TMA-3. COX2/PPARG immunoreactivity significantly increased from nevi to primary MM and metastases; COX2 positivity was associated with advanced Clark levels and shorter recurrence-free survival. Patients with PPARG-positive metastases and biomodulatory metronomic chemotherapy alone or combined with COX2/PPARG-targeting showed a significantly prolonged progression-free survival. Regarding primary MM, COX2 expression indicates an increased risk of tumor recurrence. In metastatic MM, PPARG expression may be a predicitive marker for response to biomodulatory stroma-targeted therapy.